Variantes alélicas de CYP2D6
4, *6 Y *10 en una muestra de residentes del estado Aragua, Venezuela
Bibliographic Data
| ID | 15534608 |
|---|---|
| Authors | Carlos Flores-Angulo (University of Carabobo, corresponding author), Cecilia Villegas (0000-0002-9066-1763, University of Carabobo), Yuselin Mora (0000-0002-3242-7186, University of Carabobo), José Antonio Martínez (0000-0001-7380-3080, University of Carabobo), Teresa Oropeza (University of Carabobo), Nancy Moreno (0000-0003-2533-2733, University of Carabobo) |
| Year | 2015 |
| Volume | 32 |
| Issue | 4 |
| Pages | 746-746 |
| Publication date | 2015-12-06 |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | Revista Peruana de Medicina Experimental y Salud Pública (JOURNAL) |
| Journal identifiers | ISSN: 1726-4634 • E-ISSN: 1726-4642 |
| Publisher | National Institute of Health of Peru (PUBLISHER • PE) |
| DOI | 10.17843/rpmesp.2015.324.1767 |
| PMID | 26732924 |
| OpenAlex | W2196157610 |
| Language | ES |
| References cited | 2 |
The aim of this study was to determine the CYP2D6: * 4, * 6 and * 10 gene variants frequency and to predict the metabolizer phenotype in a sample of 145 unrelated apparently healthy individuals residing in the state of Aragua, Venezuela. Genotypes were determined by Polymerase chain reaction assays followed by restriction endonucleases digestion. The metabolizer phenotype prediction was made based on the activity score system. The frequencies of CYP2D6 * 4, * 6 and * 10 allelic variants were 14.5%, 0.3% and 1%. A significant percentage of individuals were categorized as heterozygote-extensive/intermediate (23.5%) and poor metabolizers (4.1%), this information has potential clinical impact, because the CYP2D6 protein is involved in the metabolism of drugs frequently prescribed as: carvedilol, captopril, chloroquine, codeine, fluoxetine, fluvastatin, haloperidol, idarubicin, indinavir, imatinib, loperamide, nifedipine, ondansetron and tamoxifen
Biology · CYP2D6 · Gene · Genotype · Biosimilars and Bioanalytical Methods · Drug-Induced Hepatotoxicity and Protection · Medicine · Pharmacogenetics and Drug Metabolism · Genetics · Pharmacology
| Highly cited | No |
|---|